Foghorn Therapeutics Valuation
| FHTX Stock | USD 5.26 0.16 2.95% |
At this time, the firm appears to be undervalued. Foghorn Therapeutics shows a prevailing Real Value of $6.67 per share. The current price of the firm is $5.26. Our model computes the value of Foghorn Therapeutics from reviewing the firm fundamentals such as Current Valuation of 150.98 M, shares outstanding of 58.58 M, and Profit Margin of (2.94) % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Foghorn Therapeutics' valuation include:
Price Book 10.707 | Enterprise Value | Enterprise Value Ebitda (1.21) | Price Sales 12.5679 | Enterprise Value Revenue 6.5162 |
Undervalued
Today
Please note that Foghorn Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Foghorn Therapeutics is based on 3 months time horizon. Increasing Foghorn Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Foghorn Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Foghorn Stock. However, Foghorn Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.26 | Real 6.67 | Target 11.67 | Hype 5.23 |
The intrinsic value of Foghorn Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Foghorn Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Foghorn Therapeutics helps investors to forecast how Foghorn stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Foghorn Therapeutics more accurately as focusing exclusively on Foghorn Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Foghorn Therapeutics' intrinsic value based on its ongoing forecasts of Foghorn Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Foghorn Therapeutics' closest peers.
Foghorn Therapeutics Cash |
|
Foghorn Therapeutics Total Value Analysis
Foghorn Therapeutics is currently anticipated to have valuation of 150.98 M with market capitalization of 308.14 M, debt of 37.13 M, and cash on hands of 373.5 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Foghorn Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
150.98 M | 308.14 M | 37.13 M | 373.5 M |
Foghorn Therapeutics Investor Information
About 18.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.14. Foghorn Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Foghorn Therapeutics' liquidity, profitability, solvency, and operating efficiency, Foghorn Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Foghorn Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Foghorn Therapeutics has an asset utilization ratio of 7.96 percent. This suggests that the Company is making $0.0796 for each dollar of assets. An increasing asset utilization means that Foghorn Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Foghorn Therapeutics Profitability Analysis
Based on Foghorn Therapeutics' profitability indicators, Foghorn Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Foghorn Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2017-12-31 | Previous Quarter -17.9 M | Current Value -15.8 M | Quarterly Volatility 7.1 M |
For Foghorn Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Foghorn Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Foghorn Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Foghorn Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Foghorn Therapeutics over time as well as its relative position and ranking within its peers.
Foghorn Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Foghorn Therapeutics is estimated to be -0.315 with future projections ranging from a low of -0.37 to a high of -0.27. Foghorn Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -1.14. Please be aware that the consensus of earnings estimates for Foghorn Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Foghorn Therapeutics Earnings Estimation Breakdown
The calculation of Foghorn Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Foghorn Therapeutics is estimated to be -0.315 with the future projection ranging from a low of -0.37 to a high of -0.27. Please be aware that this consensus of annual earnings estimates for Foghorn Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.37 Lowest | Expected EPS | -0.27 Highest |
Foghorn Therapeutics Earnings Projection Consensus
Suppose the current estimates of Foghorn Therapeutics' value are higher than the current market price of the Foghorn Therapeutics stock. In this case, investors may conclude that Foghorn Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Foghorn Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 10 | 58.34% | 0.0 | -0.315 | -1.14 |
Foghorn Therapeutics Ownership Allocation
Foghorn Therapeutics holds a total of 58.58 Million outstanding shares. The majority of Foghorn Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Foghorn Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Foghorn Therapeutics. Please pay attention to any change in the institutional holdings of Foghorn Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Foghorn Therapeutics Profitability Analysis
The company reported the previous year's revenue of 22.6 M. Net Loss for the year was (86.62 M) with loss before overhead, payroll, taxes, and interest of (59.41 M).About Foghorn Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Foghorn Therapeutics. We calculate exposure to Foghorn Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Foghorn Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 26 M | 27.3 M | |
| Pretax Profit Margin | (3.45) | (3.62) | |
| Operating Profit Margin | (4.09) | (4.29) | |
| Net Loss | (3.45) | (3.62) | |
| Gross Profit Margin | (119.90) | (125.89) |
Foghorn Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Foghorn Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Foghorn we look at many different elements of the entity such as Foghorn's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Foghorn Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Foghorn Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Foghorn Therapeutics' worth.Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.